Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan.
BACKGROUND: Artesunate plus sulphadoxine-pyrimethamine (AS+SP) is now first-line treatment for Plasmodium falciparum infection in several south Asian countries, including Afghanistan. Molecular studies provide a sensitive means to investigate the current state of drug susceptibility to the SP compon...
Prif Awduron: | Awab, G, Pukrittayakamee, S, Jamornthanyawat, N, Yamin, F, Dondorp, A, Day, N, White, N, Woodrow, C, Imwong, M |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
BioMed Central
2013
|
Eitemau Tebyg
-
A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan
gan: Jamornthanyawat, N, et al.
Cyhoeddwyd: (2014) -
Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
gan: Rakmark, K, et al.
Cyhoeddwyd: (2020) -
Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
gan: Kasama Rakmark, et al.
Cyhoeddwyd: (2020-07-01) -
Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria.
gan: Karema, C, et al.
Cyhoeddwyd: (2010) -
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction
gan: Awab, GR, et al.
Cyhoeddwyd: (2016)